The primary objective is to obtain insight in regional differences in lung volume and ventilation distribution during apnea of prematurity and its farmacological treatment. Furthermore, the effect on these parameters due to position changes and non-…
ID
Source
Brief title
Condition
- Neonatal respiratory disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The effects of apnea/coffeine and dopram treatment/surfactant
administration/positional changes on functional residual volume, tidal volume
and ventilation distribution.
Secondary outcome
During the study, all patients will be monitored according to clinical protcol.
Of the available parameters, the following will be registered: heart rate,
breathing frequency, transcutaneous oxygen and carbondioxide tension, current
non-invasive respiratory support pressure and fractional oxygen concentration
(FiO2). Furthermore, patient caracteristics will be obtained like gestational
age, birth weight, age and diagnosis.
Background summary
Respiratory failure is relatively common in premature infants, mostly caused by
apnea of prematurity and respiratory distress syndrome (RDS). Regular treatment
comprises of non-invasive respiratory support, combined with position changes
and - where needed - additional caffeine/dopram (apnea) and/or surfactant
(RDS). The latter is currently administered through an endotracheal catheter
during spontaneous breathing. Although this intervention is known to effect
lung volume, it is unclear whether this effect is homogeneous. Insight in
distribution of lung volume and ventilation is of importance since (regional)
collapse and overdistension have been demonstrated to be major risk factors in
development of secundary lung damage. Until recently, bedside tools lacked for
registration of (regional) changes in lung volume and ventilation. However, two
non-invasive techniques have been developed for monitoring these changes:
electrical impedance tomography (EIT) and respiratory inductance
plethysmography (RIP).
Study objective
The primary objective is to obtain insight in regional differences in lung
volume and ventilation distribution during apnea of prematurity and its
farmacological treatment. Furthermore, the effect on these parameters due to
position changes and non-invasive administration of surfactant will be studied.
Study design
An observational study of regular treatment.
Study burden and risks
The study comprises of observations of daily regular treatment and hence is of
no extra strain to the patient. Both monitoring techniques have been proven to
be safe and have been frequently used in research at our department.
Meibergdreef 9
1105 AZ Amsterdam
NL
Meibergdreef 9
1105 AZ Amsterdam
NL
Listed location countries
Age
Inclusion criteria
non-invasive respiratory support
premature infants below 34 weeks of gestational age
written informed consent
Exclusion criteria
congenital anomalies of the thorax
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL39939.018.12 |